AbbVie Says Q2 2026 Includes $291M Bought IPR&D Expense, Impacting GAAP And Adj Diluted EPS By $0.17; Sees FY2026 Adj Diluted EPS At $13.91-$14.11 ; Sees Q2 2026 Adj Diluted EPS At $3.57-$3.61

뉴스 본문을 불러오고 있어요.

AbbVie Says Q2 2026 Includes $291M Bought IPR&D Expense, Impacting GAAP And Adj Diluted EPS By $0.17; Sees FY2026 Adj Diluted EPS At $13.91-$14.11 ; Sees Q2 2026 Adj Diluted EPS At $3.57-$3.61 | 웨이프 WAPE

AbbVie Says Q2 2026 Includes $291M Bought IPR&D Expense, Impacting GAAP And Adj Diluted EPS By $0.17; Sees FY2026 Adj Diluted EPS At $13.91-$14.11 ; Sees Q2 2026 Adj Diluted EPS At $3.57-$3.61

기사 요약

관련 종목

댓글 —